HN1L Promotes Migration and Invasion of Breast Cancer by Up-regulating the Expression of HMGB1

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2020 Nov 16

PMID 33191617

Citations 12

Authors

Dechuang Jiao

Jingyang Zhang

Ping Chen

Xuhui Guo

Jianghua Qiao

Jiujun Zhu

Lina Wang

Zhenduo Lu

Zhenzhen Liu

Affiliations

Soon will be listed here.

Abstract

Recent reports showed that haematological and neurological expressed 1-like (HN1L) gene participated in tumorigenesis and tumour invasion. However, the expression and role of HN1L in breast cancer remain to be investigated. Here, bioinformatics, western blot and immunohistochemistry were used to detect the expression of HN1L in breast cancer. Wound healing, transwell assay, immunofluorescence assay and mass spectrum were used to explore the role and mechanism of HN1L on the migration and invasion of breast cancer, which was confirmed in vivo using a nude mice model. Results showed that HN1L was significantly over-expressed in breast cancer tissues, which was positively correlated with M metastasis of breast cancer patients. Silencing HN1L significantly inhibited the invasion and metastasis of breast cancer cells in vitro and lung metastasis in nude mice metastasis model of breast cancer. Mechanistically, HN1L interacted with HSPA9 and affected the expression of HMGB1, playing a key role in promoting the invasion and metastasis of breast cancer cell. These results suggested that HN1L was an appealing drug target for breast cancer.

Citing Articles

Replication factor C4, which is regulated by insulin-like growth factor 2 mRNA binding protein 2, enhances the radioresistance of breast cancer by promoting the stemness of tumor cells.

Zhu X, Li P, Qu H, Ai X, Zhao Z, He J Hum Cell. 2025; 38(3):65.

PMID: 40053279 DOI: 10.1007/s13577-025-01197-9.

Unveiling epigenetic regulatory elements associated with breast cancer development.

Jardanowska-Kotuniak M, Draminski M, Wlasnowolski M, Lapinski M, Sengupta K, Agarwal A bioRxiv. 2024; .

PMID: 39605637 PMC: 11601335. DOI: 10.1101/2024.11.12.623187.

Supramolecular Nanoparticles of Histone and Hyaluronic Acid for Co-Delivery of siRNA and Photosensitizer In Vitro.

Hu M, Bao J, Zhang Y, Wang L, Zhang Y, Zhang J Int J Mol Sci. 2024; 25(10).

PMID: 38791462 PMC: 11121309. DOI: 10.3390/ijms25105424.

Multiple functions of HMGB1 in cancer.

Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B Front Oncol. 2024; 14:1384109.

PMID: 38725632 PMC: 11079206. DOI: 10.3389/fonc.2024.1384109.

Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.

Wang S, Wu X, Wu X, Cheng J, Chen Q, Qi Z BMC Cancer. 2024; 24(1):156.

PMID: 38291366 PMC: 10829303. DOI: 10.1186/s12885-024-11920-8.

References

Ravindranathan P, Pasham D, Goel A . Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. Carcinogenesis. 2019; 40(3):412-421. PMC: 6514448. DOI: 10.1093/carcin/bgy184. View

Davalos A, Kawahara M, Malhotra G, Schaum N, Huang J, Ved U . p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol. 2013; 201(4):613-29. PMC: 3653366. DOI: 10.1083/jcb.201206006. View

Zhang G, He X, Ren C, Lin J, Wang Q . Long noncoding RNA PCA3 regulates prostate cancer through sponging miR-218-5p and modulating high mobility group box 1. J Cell Physiol. 2018; 234(8):13097-13109. DOI: 10.1002/jcp.27980. View

Sawaki M, Shien T, Iwata H . TNM classification of malignant tumors (Breast Cancer Study Group). Jpn J Clin Oncol. 2018; 49(3):228-231. DOI: 10.1093/jjco/hyy182. View

Lu K, Patterson A, Wang L, Marquez R, Atkinson E, Baggerly K . Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004; 10(10):3291-300. DOI: 10.1158/1078-0432.CCR-03-0409. View

Zhang J, Shao S, Han D, Xu Y, Jiao D, Wu J . High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. Int J Oncol. 2018; 53(2):659-671. PMC: 6017266. DOI: 10.3892/ijo.2018.4420. View

Varisli L, Gonen-Korkmaz C, Debelec-Butuner B, Erbaykent-Tepedelen B, Muhammed H, Bogurcu N . Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in prostate cells. DNA Cell Biol. 2011; 30(6):419-29. DOI: 10.1089/dna.2010.1128. View

Singh M, Yelle N, Venugopal C, Singh S . EMT: Mechanisms and therapeutic implications. Pharmacol Ther. 2017; 182:80-94. DOI: 10.1016/j.pharmthera.2017.08.009. View

Horiuchi D, Camarda R, Zhou A, Yau C, Momcilovic O, Balakrishnan S . PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016; 22(11):1321-1329. PMC: 5341692. DOI: 10.1038/nm.4213. View

10.

Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P . Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A. 2014; 111(24):8838-43. PMC: 4066479. DOI: 10.1073/pnas.1320769111. View

11.

Mortimer J, Shively J . Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA. J Nucl Med. 2018; 60(1):23-25. DOI: 10.2967/jnumed.118.220905. View

12.

Lin L, Zhong K, Sun Z, Wu G, Ding G . Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2011; 138(1):11-22. DOI: 10.1007/s00432-011-1067-0. View

13.

Chen R, Zhu S, Fan X, Wang H, Lotze M, Zeh 3rd H . High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology. 2017; 67(5):1823-1841. PMC: 5906197. DOI: 10.1002/hep.29663. View

14.

Liu Y, Choi D, Sheng J, Ensor J, Liang D, Rodriguez-Aguayo C . HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. 2017; 10(1):212-227. PMC: 5768915. DOI: 10.1016/j.stemcr.2017.11.010. View

15.

Zhang X, Yang X, Zhu S, Li Q, Zou N . Radiosensitization of esophageal carcinoma cells by knockdown of HMGB1 expression. Oncol Rep. 2018; 41(3):1960-1970. DOI: 10.3892/or.2018.6923. View

16.

Starenki D, Hong S, Lloyd R, Park J . Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene. 2014; 34(35):4624-34. PMC: 4451452. DOI: 10.1038/onc.2014.392. View

17.

Jiao D, Zhang J, Chen P, Guo X, Qiao J, Zhu J . HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1. J Cell Mol Med. 2020; 25(1):397-410. PMC: 7810958. DOI: 10.1111/jcmm.16090. View

18.

Jin H, Ji M, Chen L, Liu Q, Che S, Xu M . The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. J Exp Clin Cancer Res. 2016; 35:42. PMC: 4784366. DOI: 10.1186/s13046-016-0316-0. View

19.

Nur Husna S, Tan H, Mohamud R, Dyhl-Polk A, Wong K . Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol. 2018; 10:1758835918808509. PMC: 6236629. DOI: 10.1177/1758835918808509. View

20.

Varisli L, Gonen-Korkmaz C, Syed H, Bogurcu N, Debelec-Butuner B, Erbaykent-Tepedelen B . Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells. Mol Cell Endocrinol. 2011; 350(1):107-17. DOI: 10.1016/j.mce.2011.11.027. View